HTGF backs €1.45m t-cell round

HTGF joins Constantin Bastian Leander Venture Capital and the Brandberg state development bank as backers of the company.

The investor says the firm's patented technology, which has broad applications and addresses a multi-billion euro market, was key to its decision to invest. Financing will be used to continue development of t-cell's product and validate its platform technology, enabling the firm to proceed to clinical studies.

Company
t-cell Europe is a Berlin-based developer of T-cell-based therapies based on its own platform technology. Its first product will be used in conjunction with kidney transplants to prevent immune system overreactions and improve transplant success rates.

t-cell is a spin-off from the Berlin-Brandenburg Centre for Regnerative Therapies.

People
Dr Caroline Fichtner worked on the deal for HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds